After vowing to conduct a full audit on the Democratic national political strategy because of the party’s 2024 election losses, Democratic National Committee Chairman Ken Martin says the findings of ...

Like all other BMW models, the 5-Series is being updated as part of the carmaker’s Neue Klasse era, adopting the new styling of recent concepts and the all-electric iX3. However, it appears BMW is ...

Recursion Pharmaceuticals, Inc. (RXRX) recently received a notable upgrade from JP Morgan analyst Eric Joseph, who shifted his rating to “Overweight” on December 17, 2025. This upgrade comes as the ...

Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...

Recent victories by Democratic gubernatorial candidates in New Jersey and Virginia and for seats on the Georgia Public Service Commission have led outlets like Politico to brand the outcomes as the ...

So, you’re looking to get better at coding with Python, and maybe you’ve heard about LeetCode. It’s a pretty popular place to practice coding problems, especially if you’re aiming for tech jobs.

Mayor-elect Zohran Mamdani now says the NYPD should be responsible for responding to domestic violence incidents, backtracking Wednesday on his past controversial comments. The socialist Queens ...

From intern to editor, Damian Adams' story reads like a well-written novel where he steadily worked to become the youngest-ever editor of South Africa's leading motoring publication, CAR Magazine. He ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please send the good word—or the bad—from your shop to Darren ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...